Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial

Gismondi, Ronaldo A. O. C.; Oigman, Wille; Bedirian, Ricardo; Pozzobon, Cesar Romaro; Ladeira, Marcia Cristina Boaventura; Neves, Mário Fritsch

doi:10.1177/1470320315573681

Cited by 16 publications

(11 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Benazepril is a commonly used ACEI drug that has been used for the treatment of hypertension and heart failure [ 14 , 15 ]. Recently, benazepril has been shown to generate a strong flow-mediated vasodilation response and a remarkable reduction in C-reactive protein in diabetic patients [ 16 ]. Meanwhile, BH has been widely used for renal diseases, such as renal hypertension, renal failure and DN [ 17 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression

Feng

Wang

et al. 2017

BMC Nephrol

View full text Add to dashboard Cite

BackgroundThis study aimed to investigate the effects of benazepril hydrochloride (BH) on proteinuria and ANGPTL-4 expression in a diabetic nephropathy (DN) rat model.MethodsA total of 72 Wistar male rats were randomly divided into three groups: normal control (NC), DN group and BH treatment (BH) groups. The DN model was induced by streptozotocin (STZ). Weight, glucose, proteinuria, biochemical indicators and the kidney weight index were examined at 8, 12 and 16 weeks. In addition, ANGPTL-4 protein and mRNA expressions were assessed by immunohistochemistry and qRT-PCR, respectively. Relationships between ANGPTL-4 and biochemical indicators were investigated using Spearman analysis.ResultsWeight was significantly lower but glucose levels were significantly higher in both the DN and BH groups than in the NC group (P < 0.05). Compared with the DN group, proteinuria, urea, creatinine, triglycerides and total cholesterol levels were decreased, whereas the albumin level was increased after BH treatment (all P < 0.05). Furthermore, BH diminished kidney volume and ameliorated the pathological changes associated with DN. ANGPTL-4 expression was significantly decreased after BH treatment, and ANGPTL-4 expression was highly correlated with biochemical indicators of DN (P < 0.05).ConclusionsBenazepril hydrochloride improves DN and decreases proteinuria by decreasing ANGPTL-4 expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression

Feng

Wang

et al. 2017

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…Based on a maximum type I error of 0.05 and a standard deviation of 3.5%, a sample size of 14 patients in each group would have 80% power to find a difference ≥ 4% in FMD. The calculation of the sample size used the expected FMD difference between the benazepril and losartan groups according to the design of the original study 9 . The statistical analysis was performed using a significance level of 5% and the software Statistica 12 (Statsoft Inc, Tulsa, OK, USA).…”

Section: Methodsmentioning

confidence: 99%

Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics

Gismondi

Bedirian

Pozzobon

et al. 2015

Arquivos Brasileiros De Cardiologia

Self Cite

View full text Add to dashboard Cite

BackgroundStudies suggest that statins have pleiotropic effects, such as reduction in blood pressure, and improvement in endothelial function and vascular stiffness.ObjectiveTo analyze if prior statin use influences the effect of renin-angiotensin-aldosterone system inhibitors on blood pressure, endothelial function, and vascular stiffness.MethodsPatients with diabetes and hypertension with office systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg had their antihypertensive medications replaced by amlodipine during 6 weeks. They were then randomized to either benazepril or losartan for 12 additional weeks while continuing on amlodipine. Blood pressure (assessed with ambulatory blood pressure monitoring), endothelial function (brachial artery flow-mediated dilation), and vascular stiffness (pulse wave velocity) were evaluated before and after the combined treatment. In this study, a post hoc analysis was performed to compare patients who were or were not on statins (SU and NSU groups, respectively).ResultsThe SU group presented a greater reduction in the 24-hour systolic blood pressure (from 134 to 122 mmHg, p = 0.007), and in the brachial artery flow-mediated dilation (from 6.5 to 10.9%, p = 0.003) when compared with the NSU group (from 137 to 128 mmHg, p = 0.362, and from 7.5 to 8.3%, p = 0.820). There was no statistically significant difference in pulse wave velocity (SU group: from 9.95 to 9.90 m/s, p = 0.650; NSU group: from 10.65 to 11.05 m/s, p = 0.586).ConclusionCombined use of statins, amlodipine, and renin-angiotensin-aldosterone system inhibitors improves the antihypertensive response and endothelial function in patients with hypertension and diabetes.

show abstract

“…The tests were carried out with the patient in the supine position and with the right arm compressed for 5 min using a cuff. The right brachial artery diameter was recorded before cuff inflation, and at 30, 60, and 90 s after cuff deflation, and the highest of these three values was used to calculate the maximum FMD as a percentage of increase above the baseline diameter [22, 23]. …”

Section: Methodsmentioning

confidence: 99%

Correlation between Diastolic Function and Endothelial Function in Patients with Type 2 Diabetes and Hypertension

Bedirian

Neves

Oigman

et al. 2016

TOCMJ

Self Cite

View full text Add to dashboard Cite

Background:Endothelial dysfunction may be involved in the pathophysiology of cardiac abnormalities in patients with diabetes mellitus (DM). A correlation between endothelial dysfunction and diastolic dysfunction in patients with type 1 DM has been demonstrated, but this relationship has not been well investigated in type 2 DM.Objective:Compare groups of patients with type 2 DM and hypertension with and without diastolic dysfunction using endothelial function indexes, and to assess whether correlations exist between the diastolic function and the endothelial function indexes.Method:This was a cross-sectional study of 34 men and women with type 2 DM and hypertension who were aged between 40 and 70 years and were categorized based on assessments of their Doppler echocardiographic parameters as having normal (14 patients) and abnormal (20 patients) diastolic function. Flow-mediated dilatation (FMD) assessments of the brachial artery evaluated the patients’ endothelial function.Results:The mean maximum FMD was 7.15 ± 2.80% for the patients with diastolic dysfunction and it was 11.85 ± 4.77% for the patients with normal diastolic function (p = 0.004). Correlations existed between the maximum FMD and the E/e' ratio (p = 0.040, r = -0.354) and the early wave velocity (e') at the lateral mitral annulus (p = 0.002, r = 0.509).Conclusion:The endothelial function assessed by FMD was worse in hypertensive diabetic patients with diastolic dysfunction. There were correlations between the diastolic function indexes and the endothelial function indexes in our sample.

show abstract

Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial

Cited by 16 publications

References 46 publications

Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression

Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression

Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics

Correlation between Diastolic Function and Endothelial Function in Patients with Type 2 Diabetes and Hypertension

Contact Info

Product

Resources

About